EP2048152A1 — Fused ring spiroketal derivative and use thereof as drug for treating diabetes
Assigned to Chugai Pharmaceutical Co Ltd · Expires 2009-04-15 · 17y expired
What this patent protects
Provided are a compound represented by Formula (I): wherein R 1 , R 2 , R 3 , and R 4 are each independently selected from a hydrogen atom, a C 1-6 alkyl group which may be substituted, a C 7-14 aralkyl group which may be substituted and -C(=O)Rx; n denotes an integer se…
USPTO Abstract
Provided are a compound represented by Formula (I): wherein R 1 , R 2 , R 3 , and R 4 are each independently selected from a hydrogen atom, a C 1-6 alkyl group which may be substituted, a C 7-14 aralkyl group which may be substituted and -C(=O)Rx; n denotes an integer selected from 1 and 2; and ring Ar is selected from the groups represented by the following Formula (a) to (f). , or a prodrug thereof or a pharmaceutically acceptable salt thereof as well as a pharmaceutical agent and a pharmaceutical composition containing such a compound or a prodrug thereof, or a pharmaceutically acceptable salt thereof.
Drugs covered by this patent
- Steglatro (ERTUGLIFLOZIN) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.